| 2026 Consensus Statement Update | 2022 Consensus Statement |
|---|---|
| Scenario 3 Patients with recurrence under or within 6 months after the end of adjuvant trastuzumab or trastuzumab plus pertuzumab (IV or SC) based therapy: 3-1 T-DXd is the preferred first line treatment. Trastuzumab emtansine (T-DM1) is an alternative option for patients ineligible for T-DXd. 3-2 Consider the addition of pertuzumab to T-DXd, especially if adjuvant pertuzumab has not been used. | Scenario 2 Patients with recurrence under adjuvant therapy with chemotherapy with trastuzumab or trastuzumab plus pertuzumab, or relapse within 6 months after the end of adjuvant therapy: Trastuzumab deruxtecan or T-DM1 is preferred first line treatment. |
3-1 References
DB-03, EMILIA Quality of evidence: I; Strength of recommendation: A
3-2 References
DB-07, DB-09 Quality of evidence: II; Strength of recommendation: B